Key result
Integrated care models combining physical and psychosocial care are necessary to effectively manage comorbid depression and improve outcomes in patients with coronary heart disease.
Answers are grounded in this paper and cite their sources.
The editorial advocates for integrated care pathways combining physical and psychosocial care to manage comorbid depression in patients with coronary heart disease, rather than relying on screening alone.
Coronary heart disease (CHD) is a leading cause of morbidity and mortality and has significant human and economic consequences. Many people who survive have significant psychological distress, and diminished quality of life and failure to return to work or resume normal family and social roles are not uncommon. Increased attention has been focused on the role of depression, both as a predictor and a consequence of CHD,1–5 especially myocardial infarction.6–8 When depression is linked with CHD the outcome inevitably increases disease burden.9 The importance of early detection and early referral for treatment before hospital discharge may be an optimum moment along the care pathway. Depression is a common psychiatric illness that, according to World Health Organization estimates, will be the second most important cause of disability by 2020.10 Major depression affects 1 in 20 of the population during their lifetime.11 There is a higher prevalence of comorbid depression in people with physical health problems when compared to the prevalence of depression in the general population.12 The comorbid state of depression incrementally worsens health compared with depression alone, with angina, arthritis, asthma and diabetes, and with any combination of these chronic diseases without depression.13 There are difficulties in identifying depression in comorbid physical health, with general practitioners being able to detect only 23% of comorbid depression versus 94% for depression alone.14 Identification of comorbid depression in CHD is essential for getting people on to the correct treatment pathway, hence the 2008 American Heart Association’s recommendation that all patients with CHD should be screened as part of routine care to identify those who might benefit from additional evaluation or treatment.15 Attention has been placed on case identification instruments that can help clinicians to identify depression in at risk populations and then go on to apply more detailed rating to confirm diagnosis before treatment. Pooled evidence generated from the National Institute for Health and Clinical Excellence’s review on depression in long-term conditions16 identified that the two-item case-finding ‘Whooley questions’ produced a sensitivity of 0.95 but a specificity of only 0.66. For cardiac populations, the Patient Health Questionnaire (PHQ-9) has reasonable sensitivity and specificity17 as do the Hospital Anxiety and Depression Scale (HADS), the Beck Depression Inventory (BDI) and the 90-item Symptom Checklist.18 Practical considerations, such as ease of use, self-administration versus observer rated, costs and format, may dictate choice of instrument.19 Guidelines recommend that if patients screen positive for depression on case identification tools,16 it would be best practice for patients to be assessed further with three non-somatic questions to further confirm positive cases for depression that may require treatment or to use diagnostic tools for depression by suitable qualified professionals. This recommendation may serve to reduce the number of false positives from screening but again requires fuller examination. There are unanswered questions about screening research. The most pressing is how effective screening is in helping positively screened and positively diagnosed patients to receive treatment and how many unintended consequences of screening arise, such as false positive screens and inappropriate prescription of treatment.20 To date there is simply insufficient evidence that the benefits from depression screening outweigh the potential harmful effects for patients with CHD. The case against routine general hospital screening and case finding instruments has been advanced on the basis that it led to little or no impact on the management of depression and on the basis of costs to benefits being too high.21,22 However, this conclusion must be questioned as those included studies were primarily based in primary care and were focused on a heterogeneous diagnostic population for those hospital based studies included in the review. They did report, however, a trend towards increased treatment uptake for patients who were positively screened and the result reported back to the clinician. However, this point in question has not been proven for CHD populations and thus is the core positioning of our argument. Most studies of depression in CHD populations have focused on myocardial infarction (MI), and moderate to severe depression occurs in around 20% of these patients, with the prevalence of minor depression being around 30%.23 The highest incidence rate for both minor and major depression is within the first month of a first MI,18 with about 10% of cases detected and treated in cardiac wards.24 The risk of developing depression continues for 18 months, and studies suggest that between 15% and 30% of post-MI patients suffer from depression.25 Depression independently has a strong prognostic effect on MI24,26,27 and has been found to be associated with a three to four times increase in the risk of subsequent cardiovascular morbidity and mortality,28 and this doubling of cardiac event risk occurs for up to two years.29 Even mild depression seems to be associated with increased morbidity and mortality.30 Why depression is a risk factor for poor prognosis remains unclear, but does not appear to be related to the extent of coronary artery disease, infarct size or left ventricular dysfunction.31 Studies have established that post-MI depression is common, with the highest risk being among those patients in hospital or early after discharge.32 It is unclear how services can best screen this group of patients to identify who is at risk of developing a depressive disorder post-discharge from hospital. Screening questions for depression have been recommended,16 but very little evidence has been generated about how they would work in routine practice with post-MI patients and if, indeed, they would positively identify and lead to patients receiving treatment for depression. One study demonstrated that both mild and major forms of post-MI depression result in significant healthcare costs (outpatient visits, re-hospitalisations) when compared to non-depressed patients.33 It is important, therefore, to examine how simple screening processes can be implemented by non-mental health specialists into routine care in an effort to treat the depression that exists within this group but also to reduce healthcare costs. This applies to mild forms of depression or depressive symptoms that may be higher in this patient group and consume higher amounts of resources compared with non-depressed post-MI patients. Screening trials have been set up to examine particular screening tools. For example, a study of the BDI found it was able to detect depression in hospital wards when administered within a relatively short space of time post-MI.34 The study did not investigate any impact of the positive depression screen on either harm ratios or management of the depression or cardiac outcome. Furthermore, a recent systematic review of depression screening in cardiovascular care concluded that no studies have examined whether screening for depression improves depressive symptoms or cardiac outcomes in patients with cardiovascular disease.35 While the value of screening for depression in cardiovascular disease is controversial, 9,20,36–38 we argue that the continued debate is only postponing the move towards an integrated approach to care. Considering the implications of early detection, early intervention, subsequent improvement in prognosis, reduced resource use and associated costs, and given the disproportionate prevalence of patients with serious and potentially life threatening depression in this population, it seems logical for health providers to screen post-CHD patients for depressive symptoms and, where appropriate, to refer them to a general practitioner stating what symptoms have emerged from the screening process. A fundamental barrier of screening for depression in patients with CHD is the lack of patient follow-up.39 Where depression was diagnosed in hospitalised patients with MI, 60%-70% of patients were still depressed one to four months’ later.40 Clinical pathways for identifying and managing comorbid depression and cardiovascular disease clearly need to consider the link between hospital care and primary health care. An integrated approach combining specialist and primary care with physical and psychosocial care is warranted. Research on such integrated models of care for depression is limited to the ‘bypassing the blues’ study, of which recently published findings are encouraging. The study found that compared with usual care telephone-delivered collaborative care for treatment of post-CABG depression resulted in improved health-related quality of life, physical functioning, and mood symptoms at eight-month follow-up.41 Depression is an important predictor of morbidity and mortality in patients with CHD, and relatively precise, rapid and easy to use screening tools are available. The challenge now lies not in the accuracy of screening tools but in the actions that need to be taken to minimise or prevent further medical complications or even death in patients with CHD. Depression and CHD are closely aligned, with each contributing to the worsening of the other. The way forward is to develop new models that acknowledge the complexity of this association and provide pathways from specialty to primary care that integrate the physical and psychosocial inclusive of screening, referral, monitoring and streamlined behavioural and physical care. Screening alone will not improve depression or CHD outcomes. It is therefore not only timely to develop and evaluate the clinical and cost effectiveness of integrated models of care for depression and CHD, it would be detrimental to continue the debate any longer.
No takes yet. Share an insight, caveat, or question.
Ski et al. (2011) conducted an editorial in Coronary heart disease and comorbid depression. Integrated care pathways was evaluated. Integrated care models combining physical and psychosocial care are necessary to effectively manage comorbid depression and improve outcomes in patients with coronary heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: